Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- Intravitreal dexamethasone for macular edema may increase Intraocular Pressure: Study
A comprehensive retrospective study published in the Graefe's Archive for Clinical and Experimental Ophthalmology investigated the impact of steroidal medications on intraocular pressure (IOP) ...
- Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea ...
- Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
Ocular Therapeutix Inc (NASDAQ:OCUL) announced topline results from the Phase 1 HELIOS study evaluating Axpaxli versus sham control in patients with moderately severe to severe non-proliferative ...
- Ocular marks early-stage trial win for diabetic retinopathy candidate
Ocular Therapeutix (OCUL stock gained on positive Phase 1 results for its retinal disease candidate Axpaxli in diabetic retinopathy. Read more here.
- Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
About AXPAXLI™ AXPAXLI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being ...
Go deeper with Google Headlines on:
Diabetic macular edema
[google_news title=”” keyword=”diabetic macular edema” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Diabetes related vision loss
- Embiid's diagnosis draws new attention to Bell's palsy
Philadelphia 76ers All-Star center Joel Embiid has been diagnosed with Bell's palsy. A facial nerve gets inflamed or injured and suddenly muscles on one side of the face become weak or paralyzed.
- Diabetes: Know Symptoms, Causes, Types And Treatment
“Common symptoms of diabetes include feeling very thirsty, urinating a lot, being more tired than usual, losing weight without trying, and having blurry vision. If you notice these signs, see a doctor ...
- How Much Weight Can You Expect To Lose on Ozempic?
Influencer Remi Bader said she lost weight using Ozempic but put on twice as much she dropped after stopping. And Chelsea Handler told "Call Her Daddy" podcast host Alex Cooper that she unknowingly ...
- 3 Foods That Make It Ridiculously Hard to Lose Belly Fat, According to Obesity Medicine Docs
"Diet is what contributes to losing or gaining fat," says Dr. Mir Ali, MD, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center. "The ...
- Signs and Symptoms of Diabetes Insipidus
Diabetes insipidus is a rare condition that causes extreme thirst and frequent urination. Headache and double vision are also possible symptoms.
Go deeper with Google Headlines on:
Diabetes related vision loss
[google_news title=”” keyword=”diabetes related vision loss” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]